目次

Table of Content

1. Executive Summary
1.1.Regional Market Share
1.2. Business Trends
1.3. Alzheimers Disease Diagnostic Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot

2. Research Methodology
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6.Market Size Estimation and Data Triangulation

3. Market Characteristics
3.1. Market Definition
3.2.Alzheimers Disease Diagnostic Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data

4. Alzheimers Disease Diagnostic Market - Industry Insights
4.1.Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability

5. Macroeconomic Indicators

6. Recent Developments
7.Market Dynamics
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends

8. Market Analysis
8.1. Porters Five Forces
8.2. PEST Analysis
8.2.1. Political
8.2.2.Economic
8.2.3.Social
8.2.4.Technological

9. Alzheimers Disease Diagnostic Market
9.1. Overview
9.2.Historical Analysis (2016-2021)
9.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

10. Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
10.1.Overview
10.2. Key Findings
10.3. Market Segmentation
10.3.1. By Type
10.3.1.1.Early Onset Alzheimers
10.3.1.1.1.By Value (USD Million) 2022-2032F
10.3.1.1.2. Market Share (%) 2022-2032F
10.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
10.3.1.2. Late Onset Alzheimers
10.3.1.2.1. By Value (USD Million) 2022-2032F
10.3.1.2.2.Market Share (%) 2022-2032F
10.3.1.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.1.3. Familial Alzheimers Disease
10.3.1.3.1. By Value (USD Million) 2022-2032F
10.3.1.3.2.Market Share (%) 2022-2032F
10.3.1.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.1.4. Others
10.3.1.4.1.By Value (USD Million) 2022-2032F
10.3.1.4.2. Market Share (%) 2022-2032F
10.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
10.3.2.By Diagnostic Test
10.3.2.1. PET
10.3.2.1.1. By Value (USD Million) 2022-2032F
10.3.2.1.2.Market Share (%) 2022-2032F
10.3.2.1.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.2.SPECT
10.3.2.2.1.By Value (USD Million) 2022-2032F
10.3.2.2.2. Market Share (%) 2022-2032F
10.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
10.3.2.3.Blood based ELISA Test
10.3.2.3.1.By Value (USD Million) 2022-2032F
10.3.2.3.2. Market Share (%) 2022-2032F
10.3.2.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.4.CSF Assays
10.3.2.4.1. By Value (USD Million) 2022-2032F
10.3.2.4.2.Market Share (%) 2022-2032F
10.3.2.4.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.5.Others
10.3.2.5.1.By Value (USD Million) 2022-2032F
10.3.2.5.2.Market Share (%) 2022-2032F
10.3.2.5.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.By End User
10.3.3.1. Clinic
10.3.3.1.1. By Value (USD Million) 2022-2032F
10.3.3.1.2.Market Share (%) 2022-2032F
10.3.3.1.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.2.Hospital
10.3.3.2.1.By Value (USD Million) 2022-2032F
10.3.3.2.2. Market Share (%) 2022-2032F
10.3.3.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.3.Diagnostic Center
10.3.3.3.1.By Value (USD Million) 2022-2032F
10.3.3.3.2.Market Share (%) 2022-2032F
10.3.3.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.4.Others
10.3.3.4.1. By Value (USD Million) 2022-2032F
10.3.3.4.2.Market Share (%) 2022-2032F
10.3.3.4.3.Y-o-Y Growth (%) 2022-2032F
11.North America Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1.By Type
11.3.2. By Diagnostic Test
11.3.3. By End User
11.4.Country
11.4.1. United States
11.4.2.Canada

12. Europe Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Type
12.3.2.By Diagnostic Test
12.3.3.By End User
12.4. Country
12.4.1.Germany
12.4.2. United Kingdom
12.4.3. France
12.4.4. Italy
12.4.5. Spain
12.4.6. Russia
12.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

13. Asia Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Type
13.3.2.By Diagnostic Test
13.3.3.By End User
13.4. Country
13.4.1.India
13.4.2. China
13.4.3. South Korea
13.4.4. Japan
13.4.5. Rest of APAC

14. Middle East and Africa Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Type
14.3.2.By Diagnostic Test
14.3.3.By End User
14.4. Country
14.4.1.Israel
14.4.2. GCC
14.4.3. North Africa
14.4.4. South Africa
14.4.5. Rest of Middle East and Africa

15. Latin America Alzheimers Disease Diagnostic Market Size & Forecast 2022A-2032F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Type
15.3.2.By Diagnostic Test
15.3.3.By End User
15.4. Country
15.4.1.Mexico
15.4.2. Brazil
15.4.3. Rest of Latin America

16. Competitive Landscape
16.1. Company market share, 2021
16.2. Key player overview
16.3. Key stakeholders

17. Company Profiles
17.1.Johnson & Johnson
17.1.1.Company Overview
17.1.2. Financial Overview
17.1.3. Key Product; Analysis
17.1.4.Company Assessment
17.1.4.1.Product Portfolio
17.1.4.2. Key Clients
17.1.4.3. Market Share
17.1.4.4. Recent News & Development (Last 3 Yrs.)
17.1.4.5. Executive Team
17.2. Novartis AG
17.3. F. Hoffmann-La Roche Ltd
17.4. Pfizer Inc.
17.5. Merck & Co.
17.6. GE Healthcare
17.7. AbbVie
17.8. Eli Lilly and Company
17.9. Daiichi Sankyo
17.10. Sysmex
17.11.Quanterix
17.12. Alector LLC
17.13. Corium Inc
17.14. TauRx Therapeutics
17.15. Cognition Therapeutics Inc
17.16. Other Prominent Players

18. Appendix

19. Consultant Recommendation